Veracyte, Inc. operates as a genomic diagnostics company in the United States. The company uses genomic technology to resolve diagnostic uncertainty. It offers Afirma Thyroid FNA Analysis solution; cytopathology testing services; and the Afirma Malignancy Classifiers to manage thyroid nodule patients. The company's products also include Percepta Bronchial Genomic Classifier solution for use in lung cancer screening and diagnosis; and Envisia Genomic Classifier solution for idiopathic pulmonary fibrosis. Veracyte, Inc. sells its products through product specialists, institutional managers, account managers, and medical science specialists. Veracyte, Inc. has research collaboration agreement with Loxo Oncology to develop medicines for patients with genetically defined cancers. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VCYT
Previous Symbol
CUSIPN/A
Phone650-243-6300
Debt
Debt-to-Equity Ratio0.32
Current Ratio9.14
Quick Ratio8.81
Price-To-Earnings
Trailing P/E Ratio-13.59
Forward P/E Ratio-17.93
P/E GrowthN/A
Sales & Book Value
Annual Sales$71.95 million
Price / Sales6.97
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.09 per share
Price / Book11.35
Profitability
EPS (Most Recent Fiscal Year)($0.91)
Net Income$-31,000,000.00
Net Margins-33.00%
Return on Equity-65.73%
Return on Assets-33.89%
Miscellaneous
Employees246
Outstanding Shares40,540,000
Market Cap$529.03 million
OptionableOptionable
Veracyte (NASDAQ:VCYT) Frequently Asked Questions
What is Veracyte's stock symbol?
Veracyte trades on the NASDAQ under the ticker symbol "VCYT."
How were Veracyte's earnings last quarter?
Veracyte Inc (NASDAQ:VCYT) announced its quarterly earnings data on Monday, October, 29th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.13. The biotechnology company had revenue of $23.47 million for the quarter, compared to analyst estimates of $21.52 million. Veracyte had a negative return on equity of 65.73% and a negative net margin of 33.00%. View Veracyte's Earnings History.
When is Veracyte's next earnings date?
What guidance has Veracyte issued on next quarter's earnings?
Veracyte issued an update on its FY 2018 earnings guidance on Monday, October, 29th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $90-91 million, compared to the consensus revenue estimate of $88.09 million.
What price target have analysts set for VCYT?
4 brokerages have issued 1 year price objectives for Veracyte's stock. Their predictions range from $11.00 to $13.00. On average, they anticipate Veracyte's share price to reach $12.10 in the next twelve months. This suggests that the stock has a possible downside of 2.7%. View Analyst Price Targets for Veracyte.
What is the consensus analysts' recommendation for Veracyte?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Veracyte.
Has Veracyte been receiving favorable news coverage?
Media coverage about VCYT stock has been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Veracyte earned a media sentiment score of 1.8 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an effect on the stock's share price in the next several days.
Are investors shorting Veracyte?
Veracyte saw a increase in short interest in November. As of November 15th, there was short interest totalling 1,592,783 shares, an increase of 58.5% from the October 31st total of 1,005,155 shares. Based on an average daily volume of 545,125 shares, the days-to-cover ratio is presently 2.9 days. Approximately 5.2% of the shares of the stock are sold short. View Veracyte's Current Options Chain.
Who are some of Veracyte's key competitors?
Some companies that are related to Veracyte include CareDx (CDNA), Natera (NTRA), InVitae (NVTA), RadNet (RDNT), Celcuity (CELC), Enzo Biochem (ENZ), Miragen Therapeutics (MGEN), Psychemedics (PMD), PotNetwork (POTN), Fulgent Genetics (FLGT), First Choice Healthcare Solutions (FCHS), CBA Florida (CBAI), OpGen (OPGN), Cancer Genetics (CGIX) and Aeon Global Health (AGHC).
Who are Veracyte's key executives?
Veracyte's management team includes the folowing people:
- Ms. Bonnie H. Anderson, Co-Founder, Chairman & CEO (Age 60)
- Mr. Christopher M. Hall, Pres & COO (Age 49)
- Mr. Keith S. Kennedy CFA, CPA, CFO & Sec. (Age 48)
- Dr. Giulia C. Kennedy Ph.D., Chief Scientific Officer & Head of Scientific, Clinical and Medical Affairs Department (Age 59)
- Mr. Ashish Kheterpal, Chief Information Officer
Who are Veracyte's major shareholders?
Veracyte's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (9.72%), Versant Venture Management LLC (10.47%), BlackRock Inc. (7.40%), Vanguard Group Inc (3.54%), Vanguard Group Inc. (3.54%) and First Light Asset Management LLC (2.93%). Company insiders that own Veracyte stock include Bonnie H Anderson, Christopher M Hall, Evan/ Fa Jones and Jesse I Treu. View Institutional Ownership Trends for Veracyte.
Which institutional investors are selling Veracyte stock?
VCYT stock was sold by a variety of institutional investors in the last quarter, including Acuta Capital Partners LLC, Bridgeway Capital Management Inc., Birchview Capital LP, Panagora Asset Management Inc. and Grandeur Peak Global Advisors LLC. Company insiders that have sold Veracyte company stock in the last year include Bonnie H Anderson, Christopher M Hall and Jesse I Treu. View Insider Buying and Selling for Veracyte.
Which institutional investors are buying Veracyte stock?
VCYT stock was bought by a variety of institutional investors in the last quarter, including Versant Venture Management LLC, BlackRock Inc., Allianz Asset Management GmbH, Renaissance Technologies LLC, Vanguard Group Inc, Vanguard Group Inc., First Light Asset Management LLC and Victory Capital Management Inc.. View Insider Buying and Selling for Veracyte.
How do I buy shares of Veracyte?
Shares of VCYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Veracyte's stock price today?
One share of VCYT stock can currently be purchased for approximately $12.44.
How big of a company is Veracyte?
Veracyte has a market capitalization of $529.03 million and generates $71.95 million in revenue each year. The biotechnology company earns $-31,000,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. Veracyte employs 246 workers across the globe.
What is Veracyte's official website?
How can I contact Veracyte?
Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-243-6300 or via email at [email protected]
MarketBeat Community Rating for Veracyte (NASDAQ VCYT)
MarketBeat's community ratings are surveys of what our community members think about Veracyte and other stocks. Vote "Outperform" if you believe VCYT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VCYT will underperform the S&P 500 over the long term. You may vote once every thirty days.
